July 22nd, 2019

MedDay Pharmaceuticals to webcast key opinion leader meeting on new treatment strategies for progressive forms of multiple sclerosis tomorrow
Read more

November 09th, 2018

MedDay Pharmaceuticals Announces Full Patient Enrollment for MD1003 Phase III Clinical Trial (SPI2) in Progressive Multiple Sclerosis
Read more

July 26th, 2018

MedDay Appoints Industry Leader Christian Chavy as Chief Executive Officer
Read more

March 16th, 2018

MedDay fait partie des six entreprises prometteuses distinguées dans le cadre du “Trophée des Futures Licornes” décerné par le magazine Challenges
Read more

October 18th, 2017

MedDay to Participate in the 7th Joint ECTRIMS – ACTRIMS Meeting in Paris, France
Read more

September 18th, 2017

MedDay Pharmaceuticals GmbH to participate at the 90th Congress of the German Society of Neurology in Leipzig, Germany
Read more

March 06th, 2017

MedDay Boosts its Research Capabilities with Profilomic Acquisition
Read more

September 28th, 2016

MedDay Strengthens its Board with Two Senior Non-Executive Directors
Read more

September 14th, 2016

Positive Preclinical Data with MD1003 (high dose pharmaceutical grade biotin) in X-Linked Adrenoleukodystrophy to be presented at European Committee for Treatment and Research in Multiple Sclerosis 2016
Read more

September 02nd, 2016

MedDay Announces Publication of MD1003 Phase IIb/III Study in the Multiple Sclerosis Journal
Read more

May 25th, 2016

MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial
Read more

April 27th, 2016

MedDay appoints Catherine Moukheibir as Chairman of its Board of Directors
Read more